DuLac Farmaceutici, an Italian wellness company, is accelerating its push into the U.S. market with the announcement that its products are now available through OneLavi.com, as it prepares to participate in the 2026 ECRM Vitamin, Weight Management & Sports Nutrition Session, scheduled for September 14-17 in Palm Beach Gardens, Florida. These developments represent strategic moves in DuLac's broader plan to significantly expand its footprint in the United States, building on consumer demand already established through Amazon U.S.
The company views the U.S. as a long-term growth market and is approaching its expansion through multiple channels rather than relying on a single sales avenue. By combining existing Amazon demand, the new OneLavi e-commerce platform, and direct engagement with retailers at ECRM, DuLac is constructing a multi-faceted presence. Gabriele Bollani, Founder and CEO of DuLac Farmaceutici, emphasized the importance of this phase, stating: "ECRM comes at an important time for DuLac because we are making a major commitment to the U.S. market. Amazon has demonstrated that American consumers are responding to our products, OneLavi gives us another important U.S. channel, and now we are ready to introduce DuLac to major retailers and build the partnerships that can take our expansion to the next level."
DuLac enters this next phase with an established base of U.S. consumer demand, evidenced by strong performance on Amazon. For instance, its Arnica Gel 98% has garnered more than 13,000 customer reviews with an average 4.5-star rating, while the Dinaven line has received over 4,000 reviews maintaining a 4.6-star average. The addition of OneLavi provides another platform to introduce its Made in Italy portfolio to American consumers, thereby broadening its online availability.
Participation in the ECRM session adds a crucial business-to-business dimension to DuLac's U.S. strategy. During the event, DuLac will engage in scheduled meetings with buyers from major health, specialty, food, drug, and mass retail channels. These interactions offer an opportunity to showcase its Italian-developed product portfolio, pharmaceutical heritage, and advanced manufacturing capabilities to potential retail partners. The company will highlight its high-concentration Arnica Gel 98% range, as well as the Dinaven and Diosmin lines.
DuLac's objective at ECRM extends beyond gaining additional points of distribution; it aims to establish lasting relationships that can support a larger and more diversified U.S. retail presence as part of its national expansion strategy. The company brings over 30 years of pharmaceutical industry expertise and pharmacy-channel experience in Italy to its U.S. efforts. Its product development and manufacturing capabilities include proprietary Arnica Montana Arricchita™ project, indoor vertical farming, micronized Diosmin MPFF technology, solvent-free Supercritical CO₂ Extraction, and manufacturing under internationally recognized GMP and ISO quality frameworks.
This combination of Italian pharmaceutical heritage, research, advanced production technologies, established Amazon consumer demand, and growing U.S. distribution provides the foundation for DuLac's next stage of growth. With Amazon already established, OneLavi now live, and scheduled meetings with major retail buyers planned through ECRM, DuLac is transitioning from initial U.S. market development to a broader national expansion strategy. The company's goal is to build a diversified U.S. presence across e-commerce, retail, wholesale, and other distribution channels, introducing more American consumers to the DuLac brand and its Italian-developed product portfolio.
